Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: John Tlumacki/The Boston Globe via Getty Images
In 2018, a record 59 new drugs were launched — a portfolio that makes it clear that development is increasingly geared toward specialty drugs, according to a new IQVIA report.
By the numbers: Almost half launched with orphan drug status for the use that was being approved, meaning they were designed to serve small patient populations.
- Oncology was the therapy with the most new launches — 16 — followed by infectious disease, which saw 12 launches.
- One-third were identified as first-in-class, and 39 were specialty drugs.
- A little less than half were approved based on trials with less than 500 people.
Small biopharmaceutical companies are playing an increasing role in the R&D ecosystem.
- Emerging drug companies held the initial patents on 64% of the drugs launched in 2018, but about half of last year's drugs ultimately came to market via a larger pharma company.
Big Pharma is spending a huge amount on R&D. The top 15 largest companies spent more than $100 billion on R&D for the first time last year.
Go deeper: Pharma's research budgets are usually bigger than its profits